Welcome to our dedicated page for Supernus Pharma SEC filings (Ticker: SUPN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Supernus Pharmaceuticals, Inc. (SUPN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Supernus is a biopharmaceutical company focused on developing and commercializing products for central nervous system (CNS) diseases, and its filings offer detailed insight into its commercial portfolio, collaborations, and pipeline.
Supernus’s current reports on Form 8-K cover a range of material events. These include announcements of quarterly financial results, where the company reports total revenues, net product sales for CNS therapies such as Qelbree, GOCOVRI, APOKYN, Trokendi XR, Oxtellar XR, ONAPGO, and other products, as well as royalty, licensing and other revenues and collaboration revenue from ZURZUVAE. Filings also describe non-GAAP measures like adjusted operating earnings and revenues excluding certain legacy products.
Other 8-K filings document corporate transactions, notably the acquisition of Sage Therapeutics, Inc. Supernus details the merger structure, consideration, contingent value rights (CVRs) tied to ZURZUVAE milestones, and the integration of Sage as a wholly owned subsidiary. These filings also outline the collaboration economics with Biogen Inc. related to ZURZUVAE, an oral treatment for postpartum depression.
Additional disclosures address operational updates, such as supply constraints for ONAPGO due to stronger than expected demand and the company’s decision to prioritize existing patients while working to rebuild inventory. Filings also announce upcoming earnings release dates and conference calls, reinforcing the company’s regular reporting cadence.
On Stock Titan, investors can use AI-powered tools to read concise summaries of Supernus’s 8-Ks and other SEC documents, quickly understand key points about CNS product performance, collaboration revenue, acquisitions, and pipeline developments, and identify items such as contingent value rights or other material agreements without manually parsing lengthy filings.
Supernus Pharmaceuticals, Inc. filed a Form 8-K to announce when it will release its next financial update. The company expects to report fourth quarter and full year 2025 financial and business results after the market closes on Tuesday, February 24, 2026.
Management, including the President and CEO Jack Khattar and Senior Vice President and CFO Tim Dec, will host a conference call and webcast on February 24, 2026 at 4:30 p.m. ET to discuss these results and answer questions. A live webcast and a 60-day replay will be available through the Investor Relations section of the company’s website.
Supernus Pharmaceuticals, Inc. received a Schedule 13G filing showing that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander collectively report beneficial ownership of 3,036,123 shares of Supernus common stock. This represents 5.3% of the outstanding common shares as of the event date.
The reporting persons have shared voting and dispositive power over all 3,036,123 shares, with no sole voting or dispositive power. They certify that the shares were not acquired for the purpose of changing or influencing control of Supernus, indicating a passive investment stance.
Supernus Pharmaceuticals, Inc. reported that on January 22, 2026 it entered into a First Amendment to its September 12, 2018 Agreement and Plan of Merger, with Reich Consulting Group, Inc. acting as Securityholder Representative.
The amendment changes the timing and payment of certain merger-related milestones. Supernus is filing the amendment as Exhibit 10.1, with limited portions omitted as confidential under Regulation S-K Item 601(b)(10)(iv), which the company states are not material and would be competitively harmful if publicly disclosed.
Dimensional Fund Advisors LP reports beneficial ownership of 2,712,341 shares of Supernus Pharmaceuticals Inc common stock, representing 4.7% of the class as of 12/31/2025, in an amended Schedule 13G filing. Dimensional has sole power to vote 2,650,157 shares and sole power to dispose of 2,712,341 shares.
The shares are owned by various investment companies, commingled funds, group trusts, and separate accounts advised or sub-advised by Dimensional or its subsidiaries, which are collectively referred to as the Funds. Dimensional may be deemed a beneficial owner for Section 13(d) purposes but expressly disclaims beneficial ownership, noting that all securities are owned by the Funds and that no single Fund is known to hold 5% or more of the class. Dimensional certifies that the holdings are in the ordinary course of business and not for the purpose of changing or influencing control of Supernus.
Supernus Pharmaceuticals director Hudson Frederick M. reported an option exercise and share acquisition. On January 9, 2026, he exercised a director stock option to buy 15,000 shares of common stock at an exercise price of $12.98 per share. The corresponding derivative position, a director stock option granted on March 1, 2017 and expiring on March 1, 2026, was reduced by 15,000 options to 0 following the transaction.
As a result of this option exercise, Hudson Frederick M. now directly owns 61,307 shares of Supernus Pharmaceuticals common stock. The filing classifies all reported holdings as directly owned, with no indirect ownership structures noted in the data provided.
A director of Supernus Pharmaceuticals, Inc. (SUPN) reported an option exercise and share acquisition. On 11/21/2025, the director exercised a Director Stock Option with an exercise price of $12.98 per share, acquiring 15,000 shares of common stock in a transaction coded "M" (option exercise). After this transaction, the director beneficially owned 119,644 shares of Supernus common stock in direct ownership form. The option originally covered 15,000 shares, was granted exercisable on 03/01/2017, and was set to expire on 03/01/2026; it now shows 0 derivative securities remaining following the reported exercise.
Supernus Pharmaceuticals (SUPN) senior officer reports equity award activity in a Form 4 filing. The Sr. VP of IP and Chief Scientific Officer reported a transaction dated 11/13/2025 involving derivative securities. The filing shows an acquisition of 1,500 Performance Share Units at an exercise price of $0, each linked to one share of common stock, leaving the officer with 1,500 derivative securities held directly. The non-derivative table indicates 13,718 shares of common stock beneficially owned directly following the reported transaction. An accompanying note explains that these Performance Share Units were originally awarded on February 22, 2022, with a portion vesting upon achievement of individual performance objectives set on May 3, 2022.
Supernus Pharmaceuticals (SUPN) reported Q3 2025 results and closed the acquisition of Sage Therapeutics. Total revenue was $192.1 million, up from $175.7 million, driven by stronger Qelbree sales and $20.2 million of collaboration revenue from ZURZUVAE. The company posted a net loss of $45.1 million versus net earnings of $38.5 million a year ago as selling, general and administrative expenses rose to $179.7 million and amortization increased to $24.3 million.
Cash and cash equivalents were $151.4 million, with marketable securities of $129.8 million. Year-to-date operating cash flow was $27.5 million. The Sage deal closed on July 31 for a total preliminary purchase price of $549.2 million, including $533.7 million in cash and contingent value rights with possible payments up to $234 million; acquired intangible assets were valued at $166.5 million (8-year life) and goodwill at $2.1 million. Q3 product highlights: Qelbree $81.4 million, GOCOVRI $40.8 million, and ONAPGO $6.8 million following its April launch. The company noted subsequent supplier constraints for ONAPGO due to stronger-than-expected demand.
Supernus Pharmaceuticals (SUPN) furnished an 8-K announcing Q3 2025 results and a supply update for ONAPGO. The company furnished a press release with financial results for the quarter ended September 30, 2025, and hosted a live webcast at 4:30 p.m. Eastern Time on November 4. The webcast will be archived on the company’s website for 60 days.
Supernus also disclosed a temporary supply constraint for ONAPGO driven by stronger than expected demand. To manage the imbalance, the company is prioritizing care for patients currently on therapy and pausing delivery to patients who have not yet started ONAPGO. Supernus is working to build inventory and aims to resume new patient initiations as soon as possible, with updates to follow.
Supernus Pharmaceuticals (SUPN) announced it will report third quarter 2025 results after the market closes on November 4, 2025.
Management will host a conference call and webcast on November 4, 2025 at 4:30 p.m. ET to discuss its financial and business results.
The announcement was furnished via a press release included as Exhibit 99.1.
FAQ
What is the current stock price of Supernus Pharma (SUPN)?
What is the market cap of Supernus Pharma (SUPN)?
